High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
Adolescent
Adult
Aged
Cities
/ epidemiology
Cross-Sectional Studies
Drug Users
/ statistics & numerical data
Epidemics
Female
HIV Infections
/ blood
HIV Seropositivity
/ epidemiology
Hepatitis B
/ blood
Hepatitis B Surface Antigens
/ analysis
Hepatitis C
/ blood
Humans
Male
Middle Aged
Mozambique
/ epidemiology
Population Surveillance
/ methods
Prevalence
Risk-Taking
Seroepidemiologic Studies
Sexual Behavior
/ statistics & numerical data
Substance Abuse, Intravenous
/ epidemiology
Surveys and Questionnaires
/ statistics & numerical data
Urban Population
/ statistics & numerical data
Young Adult
Hepatitis B
Hepatitis C
Human immunodeficiency virus
Mozambique
People who inject drugs
Prevalence
Respondent-driven sampling
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
02 Dec 2019
02 Dec 2019
Historique:
received:
17
07
2019
accepted:
22
11
2019
entrez:
4
12
2019
pubmed:
4
12
2019
medline:
30
1
2020
Statut:
epublish
Résumé
Few countries in sub-Saharan Africa know the magnitude of their HIV epidemic among people who inject drugs (PWID). This was the first study in Mozambique to measure prevalence of HIV, HBV, and HCV, and to assess demographic characteristics and risk behaviors in this key population. We used respondent-driven sampling (RDS) to conduct a cross-sectional behavioral surveillance survey of PWID in two cities of Mozambique lasting six months. Participants were persons who had ever injected drugs without a prescription. Participants completed a behavioral questionnaire and provided blood specimens for HIV, hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV) testing. We performed RDS-adjusted analysis in R 3.2 using RDSAT 7.1 weights. We enrolled 353 PWID in Maputo and 139 in Nampula/Nacala; approximately 95% of participants were men. Disease prevalence in Maputo and Nampula/Nacala, respectively, was 50.1 and 19.9% for HIV, 32.1 and 36.4% for HBsAg positivity, and 44.6 and 7.0% for anti-HCV positivity. Additionally, 8% (Maputo) and 28.6% (Nampula/Nacala) of PWID reported having a genital sore or ulcer in the 12 months preceding the survey. Among PWID who injected drugs in the last month, 50.3% (Maputo) and 49.6% (Nampula/Nacala) shared a needle at least once that month. Condomless sex in the last 12 months was reported by 52.4% of PWID in Maputo and 29.1% in Nampula/Nacala. Among PWID, 31.6% (Maputo) and 41.0% (Nampula/Nacala) had never tested for HIV. In multivariable analysis, PWID who used heroin had 4.3 (Maputo; 95% confidence interval [CI]: 1.2, 18.2) and 2.3 (Nampula/Nacala; 95% CI: 1.2, 4.9) greater odds of having HIV. Unsafe sexual behaviors and injection practices are frequent among PWID in Mozambique, and likely contribute to the disproportionate burden of disease we found. Intensified efforts in prevention, care, and treatment specific for PWID have the potential to limit disease transmission.
Sections du résumé
BACKGROUND
BACKGROUND
Few countries in sub-Saharan Africa know the magnitude of their HIV epidemic among people who inject drugs (PWID). This was the first study in Mozambique to measure prevalence of HIV, HBV, and HCV, and to assess demographic characteristics and risk behaviors in this key population.
METHODS
METHODS
We used respondent-driven sampling (RDS) to conduct a cross-sectional behavioral surveillance survey of PWID in two cities of Mozambique lasting six months. Participants were persons who had ever injected drugs without a prescription. Participants completed a behavioral questionnaire and provided blood specimens for HIV, hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV) testing. We performed RDS-adjusted analysis in R 3.2 using RDSAT 7.1 weights.
RESULTS
RESULTS
We enrolled 353 PWID in Maputo and 139 in Nampula/Nacala; approximately 95% of participants were men. Disease prevalence in Maputo and Nampula/Nacala, respectively, was 50.1 and 19.9% for HIV, 32.1 and 36.4% for HBsAg positivity, and 44.6 and 7.0% for anti-HCV positivity. Additionally, 8% (Maputo) and 28.6% (Nampula/Nacala) of PWID reported having a genital sore or ulcer in the 12 months preceding the survey. Among PWID who injected drugs in the last month, 50.3% (Maputo) and 49.6% (Nampula/Nacala) shared a needle at least once that month. Condomless sex in the last 12 months was reported by 52.4% of PWID in Maputo and 29.1% in Nampula/Nacala. Among PWID, 31.6% (Maputo) and 41.0% (Nampula/Nacala) had never tested for HIV. In multivariable analysis, PWID who used heroin had 4.3 (Maputo; 95% confidence interval [CI]: 1.2, 18.2) and 2.3 (Nampula/Nacala; 95% CI: 1.2, 4.9) greater odds of having HIV.
CONCLUSION
CONCLUSIONS
Unsafe sexual behaviors and injection practices are frequent among PWID in Mozambique, and likely contribute to the disproportionate burden of disease we found. Intensified efforts in prevention, care, and treatment specific for PWID have the potential to limit disease transmission.
Identifiants
pubmed: 31791273
doi: 10.1186/s12879-019-4655-2
pii: 10.1186/s12879-019-4655-2
pmc: PMC6889180
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1022Subventions
Organisme : U.S. President's Emergency Plan for AIDS Relief
ID : 5U2GPS002829
Références
J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S145-51
pubmed: 22797736
N Engl J Med. 2007 Apr 5;356(14):1445-54
pubmed: 17409326
Am J Public Health. 2014 Jun;104(6):e75-82
pubmed: 24825236
Nature. 2019 Jun;570(7760):189-193
pubmed: 31092927
AIDS Behav. 2015 Feb;19(2):393-404
pubmed: 25234252
AIDS Behav. 2015 Feb;19 Suppl 1:S59-67
pubmed: 25398418
Lancet. 2008 Nov 15;372(9651):1733-45
pubmed: 18817968
AIDS Behav. 2016 Apr;20(4):811-20
pubmed: 26395193
Harm Reduct J. 2009 Aug 28;6:24
pubmed: 19715601
J Psychoactive Drugs. 2008 Sep;40(3):273-9
pubmed: 19004419
AIDS Behav. 2015 Feb;19 Suppl 1:S36-45
pubmed: 25399032
PLoS One. 2015 Mar 23;10(3):e0121452
pubmed: 25798607
Harm Reduct J. 2019 Mar 21;16(1):21
pubmed: 30898120
Harm Reduct J. 2013 Aug 19;10:13
pubmed: 23957896
PLoS One. 2017 Jul 31;12(7):e0181836
pubmed: 28759595
Harm Reduct J. 2019 Apr 11;16(1):28
pubmed: 30975139
J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S3-8
pubmed: 17713423
Am J Trop Med Hyg. 2008 Sep;79(3):338-43
pubmed: 18784224
J Int AIDS Soc. 2018 Jul;21 Suppl 5:e25139
pubmed: 30033684
J Assoc Nurses AIDS Care. 2013 Nov-Dec;24(6):e35-44
pubmed: 23164598
Lancet. 2001 May 5;357(9266):1397-401
pubmed: 11356437
BMC Infect Dis. 2015 Apr 30;15:201
pubmed: 25925747
Drug Alcohol Depend. 2014 Feb 1;135:160-5
pubmed: 24382362
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
J Acquir Immune Defic Syndr. 2015 Mar 1;68 Suppl 2:S83-90
pubmed: 25723995
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):420-7
pubmed: 26226249
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
AIDS Behav. 2015 Feb;19 Suppl 1:S24-35
pubmed: 25398417
F1000Res. 2012 Jul 13;1:1
pubmed: 24358833